2 weeks Ago By ABMN Staff
Edwards Lifesciences Co. ( NYSE:EW – Get Free Report ) saw some unusual options trading on Thursday. Stock investors purchased 18,389 put options on the stock.
This represents an increase of 127% compared to the typical daily volume of 8,107 put options. Analysts Set New Price Targets EW has been the topic of a number of recent research reports. Robert W.
Baird cut Edwards Lifesciences from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $102.00 to $70.00 in a report on Thursday, July 25th.
Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft decreased their target price on Edwards Lifesciences from $103.00 to $85.
00 and set a “buy” rating for the company in a research report on Thursday, July 25th. Barclays decreased their target price on Edwards Lifesciences from $101.00 to $90.
00 and set an “overweight” rating for the company in a research report on Friday, July 26th. Finally, Piper Sandler decreased their target price on Edwards Lifesciences from $88.00 to $73.
00 and set a “neutral” rating for the company in a research report on Thursday, July 25th. Fourteen research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $82.
10. Check Out Our Latest Report on Edwards Lifesciences Edwards Lifesciences Trading Down 0.2 % Edwards Lifesciences ( NYSE:EW – Get Free Report ) last issued its quarterly earnings results on Wednesday, July 24th.
The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.
01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.
55%. The firm had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.
65 billion. During the same period in the previous year, the company posted $0.66 earnings per share.
The company’s quarterly revenue was up 6.7% compared to the same quarter last year. As a group, research analysts predict that Edwards Lifesciences will post 2.
71 earnings per share for the current year. Insider Activity In other news, VP Donald E. Bobo, Jr.
sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total transaction of $437,700.
00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $4,108,777.44.
The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website . In related news, VP Donald E. Bobo, Jr.
sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total value of $437,700.
00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $4,108,777.44.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.
95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.
35. The disclosure for this sale can be found here . In the last ninety days, insiders have sold 16,250 shares of company stock worth $1,321,988.
1.29% of the stock is owned by company insiders. Institutional Investors Weigh In On Edwards Lifesciences Institutional investors have recently added to or reduced their stakes in the stock.
Allspring Global Investments Holdings LLC boosted its holdings in shares of Edwards Lifesciences by 4.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock worth $31,603,000 after acquiring an additional 14,087 shares in the last quarter.
Empowered Funds LLC lifted its holdings in Edwards Lifesciences by 151.2% during the 1st quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock worth $1,923,000 after buying an additional 12,112 shares in the last quarter.
Cetera Advisors LLC lifted its holdings in Edwards Lifesciences by 175.1% during the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock worth $3,640,000 after buying an additional 24,242 shares in the last quarter.
TD Asset Management Inc lifted its holdings in Edwards Lifesciences by 95.1% during the 4th quarter. TD Asset Management Inc now owns 1,323,611 shares of the medical research company’s stock worth $100,925,000 after buying an additional 645,204 shares in the last quarter.
Finally, Sei Investments Co. lifted its holdings in Edwards Lifesciences by 10.8% during the 4th quarter.
Sei Investments Co. now owns 558,031 shares of the medical research company’s stock worth $42,550,000 after buying an additional 54,595 shares in the last quarter. 79.
46% of the stock is owned by institutional investors and hedge funds. Edwards Lifesciences Company Profile ( Get Free Report ) Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
See Also Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter ..
